Pulmonary Clinical Trials

For Patients

If you have been diagnosed with pulmonary diseases such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, or Pulmonary Hypertension you may be eligible to participate in a clinical research trial. Clinical research trials take place at both the East and West locations for The Oregon Clinic Pulmonary, Critical Care & Sleep Medicine.

There are different types of clinical trials you can be involved with. To learn more about the world of research, we highly recommend reading more on the U.S. National Library of Medicine website by clicking here.

If you are interested in participating in a research trial, please call the contact info that corresponds with your diagnosed disease for more information.

Pulmonary, Critical Care & Sleep Medicine East

  • Asthma 
  • COPD 
  • Lung Nodule 
  • Idiopathic Pulmonary Fibrosis 
  • Interstitial Lung Disease 
  • Pulmonary Hypertension

Contact: Meg Day | 503-963-3182 | Email

Pulmonary, Critical Care & Sleep Medicine - West

  • Asthma
  • Pulmonary Hypertension 

Contact: Stephanie Persons | 503-963-3172 | Email

For Health Professionals

AstraZeneca D3250R00023 Severe Asthma
Sana Meshesha  | 503-963-3093 | Email 
The CHRONICLE Study:  A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individual with Severe Asthma in the United States
18 + year old, with minimum 12-month diagnosis of uncontrolled or under-controlled severe asthma on high-dose ICS with additional controllers.

Bellerophon  PULSE-PHPF-001 (REBUILD)
Meg Day | 503-963-3182 | Email
A Randomized, Double-Blind, Placebo-controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated with Pulmonary Fibrosis on Long Term Oxygen Therapy
Diagnosis of IPF or ILD (except sarcoidosis).  Minimum of 12 hours per day of oxygen use with activity. (Cannot be worn with CPAP) Minimum FVC of 40% predicted.  Willing to wear an activity monitor and able to walk 100-400 meters in 6mwt.

DCRI/Boehringer-Ingelheim 1199.174 IPF and ILD
Meg Day | 503-963-3182 | Email
Idiopathic Pulmonary Fibrosis Prospective Outcome (IPF-PRO) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry.
IPF arm is in long term follow-up. Enrollment continues for Progressive Interstitial Lung Diseases other than IPF. Enrolling 40+ year old with relative decline in FVC of 10% or more, or 5-10% with worsening respiratory symptoms or increasing fibrotic changes on HRCT scan.

Fibrogen FGCL-3019-091
Meg Day | 503-963-3182 | Email
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis
CLOSED TO ENROLLMENT. IPF subjects 40-85 years of age, diagnosed in past 7 years, and not currently receiving any approved therapy for IPF FVC45-95% @ screening.  DLcO 25-95% @ screening.

FIBRONEER 1305-0014
Meg Day | 503-963-3182 | Email
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in people with Idiopathic Pulmonary Fibrosis (IPF)
Enrolling 40+ year old subjects with Idiopathic Pulmonary Fibrosis (IPF), on stable treatment of nintedanib or pirfenidone for at least 12 weeks or not on nintedanib or pirfenidone treatment for at least 8 weeks. With Forced Vital Lung Capacity (FVC) ≥45% of predicted normal and Diffusing Capacity for Carbon Monoxide (DLCO) ≥25% and <90% predicted of normal.

FIBRONEER 1305-0023
Meg Day I 503-963-3182 I Email
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung diseases.
Enrolling 18+ year old subjects with Interstitial Lung Disease (ILD) other than Idiopathic Pulmonary Fibrosis (IPF), on stable treatment of nintedanib for at least 12 weeks or not on nintedanib treatment for at least 8 weeks. With Forced Vital Lung Capacity (FVC) ≥45% of predicted normal and Diffusing Capacity for Carbon Monoxide (DLCO) ≥25% and <90% predicted of normal.

Janssen/Actelion AC-055-315 UNISUS
Sana Meshesha | 503-963-3093 | Email
A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period with Macitentan 75mg
Enrolling 18+ year old subjects with documented PAH Can be idiopathic, heritable, drug or toxin-induced or related to HIV or CTD. Must be able to complete 6mwt of 50-440 meters

PHAR Pulmonary Hypertension Association Registry
Sana Meshesha | 503-963-3093 | Email
A multicenter, prospective registry of newly evaluated patients at PHCCs in the United States who have either PAH or CTEPH.
Baseline information will be collected at the time of initial evaluation at the PHCC with follow-up data collected at approximately 6-month intervals.

United Therapeutics
Meg Day I 503-963-3182 I Email
A Randomized, Double-Blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis
IPF diagnosis per 2018 ATS guidelines.  FVC > 45% at screening, FEV1/FVC > 0.70, can be on current IPF therapy if stable x 30 days. No azathioprine, corticosteroids >20mg/day, cyclophosphamide, or rituximab.